Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Lexaria Bioscience Corp (NQ: LEXX ) 2.320 +0.170 (+7.91%) Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Lexaria Bioscience Corp < Previous 1 2 3 4 5 6 7 8 9 ... 29 30 Next > LEXX Stock Earnings: Lexaria Bioscience Misses EPS, Misses Revenue for Q3 2024 July 12, 2024 LEXX stock results show that Lexaria Bioscience missed analyst estimates for earnings per share and missed on revenue for the third quarter of 2024. Via InvestorPlace CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Dosing in Second GLP-1 Human Pilot Study July 09, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Product Safety CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Dosing in Second GLP-1 Human Pilot Study July 09, 2024 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property Product Safety Dosing is Complete in Lexaria's Second GLP-1 Human Pilot Study July 09, 2024 Via ACCESSWIRE Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy July 08, 2024 Via ACCESSWIRE Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study June 18, 2024 Via ACCESSWIRE Dosing Continues in Lexaria’s Second GLP-1 Human Pilot Study June 05, 2024 Via ACCESSWIRE CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures New Patents for Antiviral Drug Delivery, Treating Epilepsy July 08, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing Favorable Strategic Partnering with Leading GLP-1 Players June 27, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Second Round of Dosing for Human Pilot Study #2; Set to Complete Third Study Arm in Early July June 24, 2024 Via Investor Brand Network Lexaria Awards Contract For Third GLP-1 Human Pilot Study May 23, 2024 Via ACCESSWIRE 7 A-Rated Penny Stocks to Beat June Gloom June 24, 2024 Some penny stocks can be diamonds in the rough. These A-rated penny stocks are all solid picks for a portfolio this month. Via InvestorPlace HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Engages CRO for DehydraTECH GLP-1 Human Study June 18, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires CRO; Set for First Tirzepatide Molecule Study June 17, 2024 Via Investor Brand Network 7 A-Rated Biotech Stocks Worth Betting on in June June 14, 2024 A-rated biotech stocks are highly coveted because they are at the forefront – or in the midst of -- groundbreaking innovation. Via InvestorPlace Lexaria Bioscience Corp. (NASDAQ: LEXX) Grows Patent Portfolio to 43 Granted Patents Worldwide June 06, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Completion of Dosing in Second Arm of Third GLP-1 Human Pilot Study June 05, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Product Safety CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Completion of Dosing in Second Arm of Third GLP-1 Human Pilot Study June 05, 2024 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property Product Safety Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday June 04, 2024 It's time to start Tuesday with a breakdown of the biggest pre-market stock movers traders will want to know about this morning! Via InvestorPlace Why HealthEquity Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket June 04, 2024 Via Benzinga 12 Health Care Stocks Moving In Thursday's Intraday Session May 30, 2024 Via Benzinga 7 A-Rated Penny Stocks Work Betting On in H2 2024 May 30, 2024 For a growth investor, one of the top advantages of A-rated penny stocks is that they have the potential for oversized profits. Via InvestorPlace Lexaria Bioscience Corp. (NASDAQ: LEXX) Concludes First Dosing for its Second GLP-1 Human Pilot Study; Maintains Study Pace and Rollout for 2024 May 28, 2024 Via CannabisNewsWire Lexaria Bioscience Corp. (NASDAQ: LEXX) Concludes First Dosing for its Second GLP-1 Human Pilot Study; Maintains Study Pace and Rollout for 2024 May 28, 2024 Via Investor Brand Network CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Selects CRO in Third GLP-1 Human Pilot Study May 23, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Selects CRO in Third GLP-1 Human Pilot Study May 23, 2024 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Granted Two New US Patents in Hypertension, Epilepsy May 22, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Lexaria Receives Two New Medical-Treatment Patents in Hypertension and Epilepsy May 21, 2024 Via ACCESSWIRE CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Commencement of Dosing in Comprehensive GLP-1 Animal Study May 17, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Dosing Begins in Lexaria's Comprehensive GLP-1 Animal Study May 17, 2024 Via ACCESSWIRE < Previous 1 2 3 4 5 6 7 8 9 ... 29 30 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
